Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NeuroSense Therapeutics Ltd. - Ordinary Shares (NQ: NRSN )

0.9500 -0.0401 (-4.05%)
Streaming Delayed Price Updated: 3:13 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 84,774
Open 0.9801
Bid (Size) 0.9400 (90)
Ask (Size) 0.9600 (100)
Prev. Close 0.9901
Today's Range 0.9108 - 1.020
52wk Range 0.4820 - 2.330
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission
NeuroSense Therapeutics schedules an FDA Type C meeting on Nov. 6 to finalize its Phase 3 trial design for PrimeC, a potential ALS treatment. 
Via Benzinga
Exposures Product Safety
NeuroSense Advances Plans For Early Commercialization Of Potentially Groundbreaking ALS Treatment In Canada, Targeting A $100M+ Market
NeuroSense Advances Plans For Early Commercialization Of Potentially Groundbreaking ALS Treatment In Canada, Targeting A $100M+ Market 
Via News Direct

Performance

YTD
+18.75%
+18.75%
1 Month
-13.64%
-13.64%
3 Month
+17.28%
+17.28%
6 Month
-23.39%
-23.39%
1 Year
+82.76%
+82.76%

More News

Read More
EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug
Via Benzinga
NRSN Stock Earnings: NeuroSense Therapeutics Misses EPS for Q1 2024
Via InvestorPlace
NRSN Stock Earnings: NeuroSense Therapeutics Beats EPS for Q4 2023
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
NeuroSense's (NASDAQ: NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
Via Benzinga
Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
US Stocks Higher; Private Payrolls Rise By 103,000 In November
Via Benzinga
Topics Stocks
Exposures US Equities
Why SentinelOne Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why GitLab Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics’ Lead Drug Candidate, PrimeC
Via ACCESSWIRE
Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics' Lead Drug Candidate, PrimeC
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 17, 2023
Via Benzinga
Why Pliant Therapeutics Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why FARO Technologies Shares Are Trading Lower By 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Dow Drops 50 Points; Netflix Sales Top Estimates
Via Benzinga
Why Netflix Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Dow Drops 150 Points; Crude Oil Up 1%
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.